Latest research on Insulin detemir

Insulin detemir is a long-acting human insulin analogue used to maintain basal levels of insulin in diabetic individuals. It is produced using recombinant DNA technology in yeast cells. This insulin analogue has a 14-C fatty acid, myristic acid, bound to the lysine amino acid at position B29. The myristoyl side chain increases self-association and albumin binding. This along with slow systemic absorption from the injection site prolongs distribution of the hormone into tissues and results in a long duration of action. Novo Nordisk markets insulin detemir under the trade name Levemir.

Latest findings

A significant relationship between the injected dose of Insulin detemir and its duration of hypoglycemic action has been recently reported (Plank et al 2005), and such observation may influence the use of Insulin detemir in one or two injections per day to insure basal insulin levels over the 24 h period (Oiknine et al 2005). [source, 2006]
Insulin detemir acts as a full agonist of the insulin receptor but dissociates from the insulin receptor twice as fast as human insulin in vitro. [source, 2006]